C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis. Despite treatment with eculizumab, a C5 inhibitor, 72% of individuals remain anemic. Pegcetacoplan (APL‐2), a PEGylated C3 inhibitor,...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of hematology Vol. 95; no. 11; pp. 1334 - 1343
Main Authors:	Castro, Carlos, Grossi, Federico, Weitz, Ilene Ceil, Maciejewski, Jaroslaw, Sharma, Vivek, Roman, Eloy, Brodsky, Robert A., Tan, Lisa, Di Casoli, Carl, El Mehdi, Delphine, Deschatelets, Pascal, Francois, Cedric
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 01.11.2020 Wiley Subscription Services, Inc
Subjects:	Adult Anemia, Hemolytic - drug therapy Anemia, Hemolytic - etiology Anemia, Hemolytic - prevention & control Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Bilirubin Bilirubin - blood Blood diseases Chemical and Drug Induced Liver Injury - etiology Complement C3 - antagonists & inhibitors Complement C5 - antagonists & inhibitors Complement component C3 Drug Substitution Female Fever - chemically induced Hematological diseases Hematology Hemoglobin Hemoglobins - analysis Hemoglobinuria, Paroxysmal - blood Hemoglobinuria, Paroxysmal - drug therapy Hemoglobinuria, Paroxysmal - immunology Hemolysis Hemolysis - drug effects Humans L-Lactate dehydrogenase L-Lactate Dehydrogenase - blood Lactic acid Male Middle Aged Monoclonal antibodies Pancreatitis - chemically induced Paroxysmal nocturnal hemoglobinuria Pharmacodynamics Pharmacokinetics Prospective Studies Reticulocyte Count Thrombosis
ISSN:	0361-8609, 1096-8652, 1096-8652
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!